Antonio Ceriello, Italy

IRCCS MultiMedica, Milan, Italy Diabetes Research Department
Professor Antonio Ceriello is the Head of the Diabetes Research Department at IRCCS MultiMedica, Milan, Italy. Professor Ceriello has published widely in the area of diabetes with over 500 original papers and with an h-index of 106. He chaired the International Diabetes Federation (IDF) committee for the development in 2008, and in the 2011 for the update of “Guideline for Management of Postmeal Glucose ”. Currently, is the President of the European Association for the Study of Diabetes (EASD) Study Group on “Diabetes and Cardiovascular Diseases”. He also served as Board member of the “2019 European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD “. He also served as Associate Editor of “Diabetes Care” from 2003 to 2011 and Associate Editor of “Diabetic Medicine” from 2005 to 2016. From July 1st 2016 he has been appointed as Editor in Chief of “Diabetes Research and Clinical Practice”, the official IDF journal. Currently he is also in the Editorial Board of “Cardiovascular Diabetology”. Prof. Ceriello is the winner of the 2004 “Camillo Golgi Prize” of the EASD and of the 2017 of the “Hellmut Mehnert Award”, during the IDF 2017 Meeting.

Presenter of 2 Presentations

INDUSTRY SESSION

HF in T2D: perspectives from a diabetologist and a cardiologist

PLENARY SESSION

How to manage type 2 diabetes and obesity during the COVID-19 pandemic

Abstract

Abstract Body

People with diabetes compared with people without exhibit worse prognosis if affected by COVID-19 induced by the SARS-CoV2, particularly when compromising metabolic control and concomitant cardiovascular disorders are present.

This perspective article seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially also taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV2. Severe infection with SARS-CoV2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute-respiratory-distress-syndrome and renal failure. They may evolve along with multi-organ failure due to directly SARS-CoV2 infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV2-infection. Whenever possible, continuous-glucose-monitoring should be implemented to ensure stable metabolic compensation. Patients in intensive-care-unit requiring therapy for glycemic control should solely be handled by intravenous insulin using exact dosing with a perfusion device. Although not only ACE-inhibitors and angiotensin-2-receptor-blockers, but also SGLT2-inhibitors, GLP1-receptor-agonists, pioglitazone, and probably insulin seem to increase the number of ACE2-receptors on the cells utilized by SARS-CoV2 for penetration, no evidence presently exists that this might be harmful in terms of acquiring or worsening COVID-19 with unequivocal proof urgently awaited. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.

Hide